Jewish Ethics and Biotech Innovation Clash in Supreme Court's BRCA Gene Case

Should Company Be Permitted to Patent 'Breast Cancer' Gene?

‘My DNA’: Lisa Schlager addresses protesters outside the Supreme Court. Many Jewish women may owe their lives to innovative new tests that uncovered their risk of breast cancer. But they strongly feel companies should not be allowed to patent genes.
courtesy of lisa schlager
‘My DNA’: Lisa Schlager addresses protesters outside the Supreme Court. Many Jewish women may owe their lives to innovative new tests that uncovered their risk of breast cancer. But they strongly feel companies should not be allowed to patent genes.

By Anne Cohen

Published April 18, 2013, issue of April 26, 2013.
  • Print
  • Share Share
  • Single Page

Lisa Schlager waited with hundreds of other women outside the Supreme Court in Washington on April 15, hoping to hear arguments over a private company’s effort to patent a human gene that is linked to breast cancer, especially in Ashkenazi women.

Schlager, 46, has a huge stake in the controversial case, as do thousands of Jewish women.

After testing positive for the BRCA1 gene at the center of the case, Schlager underwent ovarian and breast surgery to avoid an almost nine-in-ten chance of developing cancer. Like some so-called “pre-vivors,” Schlager opposes Myriad Genetics Inc.’s patent on the gene, which is under challenge in the Supreme Court case.

“God created my DNA,” said Schlager, an official with FORCE: Facing Our Risk of Cancer Empowered, an organization that seeks to promote awareness of hereditary cancers. “No company should have the right to patent what occurs naturally in my body.”

Not all Jews agree. Some point out that if pharmaceutical companies don’t have the financial incentive provided by the patent system, they simply won’t perform the kind of lifesaving research that Myriad did in isolating the mutated versions of BRCA1 and BRCA2 genes, which occur much more frequently in Ashkenazi Jewish women.

“If you want to promote the technology, what’s the best way to do that?” asked Rebecca Eisenberg, the Robert and Barbara Luciano Professor of Law at the University of Michigan. “I think this is an area where patents are important.”

For the Supreme Court, the case hinges mostly on the narrow question of whether the genes are naturally occurring and therefore not subject to patents, or if they are the product of human ingenuity, in which case they can be patented.

The American Civil Liberties Union and the Public Patent Foundation filed the lawsuit against Myriad in 2009, challenging the seven patents held by the company on the two genes. A federal judge ruled that the patents were invalid, a decision that was later overruled by an appeals court.

Justices cited more mundane products like baseball bats to argue into which category the gene mutations should fall. Both Justice Samuel Alito and Chief Justice John Roberts seized upon the suggestion made by Myriad’s attorney, Gregory Castanias, that a baseball bat doesn’t exist until it’s isolated from the tree.


The Jewish Daily Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. In the interest of maintaining a civil forum, The Jewish Daily Forwardrequires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and The Jewish Daily Forward reserves the right to remove comments for any reason.





Find us on Facebook!
  • Move over Dr. Ruth — there’s a (not-so) new sassy Jewish sex-therapist in town. Her name is Shirley Zussman — and just turned 100 years old.
  • From kosher wine to Ecstasy, presenting some of our best bootlegs:
  • Sara Kramer is not the first New Yorker to feel the alluring pull of the West Coast — but she might be the first heading there with Turkish Urfa pepper and za’atar in her suitcase.
  • About 1 in 40 American Jews will get pancreatic cancer (Ruth Bader Ginsberg is one of the few survivors).
  • At which grade level should classroom discussions include topics like the death of civilians kidnapping of young Israelis and sirens warning of incoming rockets?
  • Wanted: Met Council CEO.
  • “Look, on the one hand, I understand him,” says Rivka Ben-Pazi, a niece of Elchanan Hameiri, the boy that Henk Zanoli saved. “He had a family tragedy.” But on the other hand, she said, “I think he was wrong.” What do you think?
  • How about a side of Hitler with your spaghetti?
  • Why "Be fruitful and multiply" isn't as simple as it seems:
  • William Schabas may be the least of Israel's problems.
  • You've heard of the #IceBucketChallenge, but Forward publisher Sam Norich has something better: a #SoupBucketChallenge (complete with matzo balls!) Jon Stewart, Sarah Silverman & David Remnick, you have 24 hours!
  • Did Hamas just take credit for kidnapping the three Israeli teens?
  • "We know what it means to be in the headlines. We know what it feels like when the world sits idly by and watches the news from the luxury of their living room couches. We know the pain of silence. We know the agony of inaction."
  • When YA romance becomes "Hasidsploitation":
  • "I am wrapping up the summer with a beach vacation with my non-Jewish in-laws. They’re good people and real leftists who try to live the values they preach. This was a quality I admired, until the latest war in Gaza. Now they are adamant that American Jews need to take more responsibility for the deaths in Gaza. They are educated people who understand the political complexity, but I don’t think they get the emotional complexity of being an American Jew who is capable of criticizing Israel but still feels a deep connection to it. How can I get this across to them?"
  • from-cache

Would you like to receive updates about new stories?




















We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.